Anakinra

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (4)
US
  • Cryopyrin-Associated Periodic Syndromes (NOMID)FDA label
  • Deficiency of Interleukin-1 Receptor Antagonist (DIRA)FDA label
  • Cryopyrin-Associated Periodic Syndromes (CAPS) KINERET is indicated for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).FDA label
Product first approved 2001Outside this platform's coverage
EU
  • Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone. COVID-19 Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ? 6 ng/ml. Periodic fever syndromes Kineret is indicated for the...
Product first approved 2002EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Rheumatoid Arthritis
Other / comorbidity
NCT04381936 · University of Oxford
2020-03-19 – 2038-09-30 · Pneumonia
What this study did
NCT07281027 · Yale University
2026-12-01 – 2030-09-30 · New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
What this study did
NCT07371689 · Assistance Publique - Hôpitaux de Paris
2026-02 – 2029-12 · PEDIATRIC ACUTE MYOCARDITIS
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT05805930 · Istituto Giannina Gaslini
2025-02-06 – 2028-05-31 · Pericarditis
What this study did
NCT05814159 · Swedish Orphan Biovitrum
2022-08-24 – 2026-06-24 · Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
What this study did
NCT05498467 · Herlev and Gentofte Hospital
2022-10-11 – 2024-08-01 · Allergic Contact Dermatitis
What this study did
NCT04362111 · University of Alabama at Birmingham
2020-08-01 – 2023-06-01 · Cytokine Storm, COVID-19
What this study did
NCT02902731 · University Hospital, Caen
2017-05-11 – 2022-11-25 · Giant Cell Arteritis
What this study did
NCT04424056 · Assistance Publique Hopitaux De Marseille
2020-09-01 – 2022-11-01 · Covid19
What this study did
NCT04330638 · University Hospital, Ghent
2020-04-03 – 2021-05-21 · COVID-19
What this study did
NCT04364009 · University Hospital, Tours
2020-04-27 – 2020-11-03 · COVID-19 Infection, ANAKINRA Treatment, Optimized Standard of Care (oSOC)
What this study did
NCT03265132 · Swedish Orphan Biovitrum
2017-09-26 – 2019-05-23 · Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
What this study did
NCT02672592 · University Hospital, Basel, Switzerland
2016-01 – 2017-06 · Hypogonadism, Metabolic Syndrome X, Obesity
What this study did
NCT02227420 · University Hospital, Basel, Switzerland
2014-10 – 2016-07 · Metabolic Syndrome, Hypersecretion; Cortisol
What this study did
NCT01705756 · Sheba Medical Center
2012-11 – 2015-06 · Familial Mediterranean Fever
What this study did
NCT00789724 · Virginia Commonwealth University
2008-11 – 2009-08 · ST Segment Elevation Acute Myocardial Infarction
What this study did
Phase 2/3 (16)
Other / comorbidity
NCT05267821 · Nationwide Children's Hospital
2022-06-14 – 2028-08-31 · Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
What this study did
NCT05926505 · Hellenic Institute for the Study of Sepsis
2023-09-06 – 2028-03 · Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID
What this study did
NCT04898231 · University of California, San Diego
2020-12-22 – 2024-04-25 · Multisystem Inflammatory Syndrome-Children
What this study did
NCT03018834 · Assistance Publique - Hôpitaux de Paris
2017-05-30 – 2022-05-30 · Acute Myocarditis
What this study did
NCT02578394 · Mid and South Essex NHS Foundation Trust
2016-04 – 2022-01-26 · Gout, Chronic Kidney Diseases
What this study did
NCT04643678 · Hamad Medical Corporation
2020-10-30 – 2021-04-30 · Covid19, Pneumonia, Cytokine Release Syndrome, Corona Virus Infection, Viral Infection
What this study did
NCT04443881 · Fundacion Miguel Servet
2020-05-08 – 2021-03-31 · COVID-19 Pnemonia
What this study did
NCT04324021 · Swedish Orphan Biovitrum
2020-04-02 – 2020-11-13 · SARS-CoV-2
What this study did
NCT01950299 · Virginia Commonwealth University
2014-07-01 – 2018-12-23 · Acute Myocardial Infarction
What this study did
NCT01809132 · Mack Mitchell
2013-09 – 2018-10 · Acute Alcoholic Hepatitis
What this study did
NCT01936909 · Virginia Commonwealth University
2014-02 – 2016-09-23 · Heart Failure
What this study did
NCT02108210 · Radboud University Medical Center
2014-06 – 2016-05 · Chronic Fatigue Syndrome
What this study did
NCT01936844 · Virginia Commonwealth University
2014-02 – 2015-05 · Heart Failure
What this study did
NCT00711503 · Steno Diabetes Center Copenhagen
2009-01 – 2012-06 · Type 1 Diabetes
What this study did
NCT01165008 · Karolinska Institutet
2003-09 – 2008-09 · Polymyositis, Dermatomyositis, Inclusion Body Myositis
What this study did
NCT00339157 · Institut National de la Santé Et de la Recherche Médicale, France
2006-05-11 – 2008-06-10 · Systemic-Onset Juvenile Idiopathic Arthritis
What this study did
Phase 2 (67)
Rheumatoid Arthritis
NCT00037648 · Amgen
2000-07 – 2003-11 · Juvenile Chronic Arthritis
What this study did
NCT00537667 · Amgen
2001-08 – 2003-06 · Rheumatoid Arthritis
What this study did
NCT00037700 · Amgen
2001-05 – 2002-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06381661 · Assistance Publique - Hôpitaux de Paris
2026-07-09 – 2031-07-09 · Sepsis
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT05611710 · Oxford University Clinical Research Unit, Vietnam
2023-01-02 – 2027-12-31 · Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra, Immuno-modulation, Anti-inflammatory Agents, Macrophage Activation Syndrome, Hyperinflammatory Syndrome, Cytokine Storm
What this study did
NCT03587701 · Andrea Vambutas
2019-01-03 – 2027-12-31 · Autoimmune Inner Ear Disease, Meniere's Disease
What this study did
NCT05177822 · Virginia Commonwealth University
2022-05-24 – 2027-12-30 · Heart Failure
What this study did
NCT04148430 · Memorial Sloan Kettering Cancer Center
2019-10-30 – 2027-10 · B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
What this study did
NCT04926467 · Baylor Research Institute
2021-07-23 – 2027-06 · Pancreatic Adenocarcinoma
What this study did
NCT07423975 · Beijing Tiantan Hospital
2026-04-08 – 2027-01-30 · Stroke Acute, Endovascular Treatment
What this study did
NCT07254000 · Monash Medical Centre
2025-06-27 – 2026-12 · Premature Infants, Very Premature Infants, Inflammation
What this study did
NCT07580079 · Marc Donath
2026-07 – 2026-12 · Postprandial Hypoglycemia, End-stage Renal Disease (ESRD), Gastrectomy, Glucose Metabolism Disorders, Inflammation, Gastric Bypass Surgery
What this study did
NCT04844814 · Assistance Publique - Hôpitaux de Paris
2022-06-02 – 2026-08-31 · Gout, Chronic Kidney Disease, Renal Transplantation
What this study did
NCT05174507 · University Hospital, Basel, Switzerland
2022-06-24 – 2026-05-01 · Postprandial Hypoglycemia
What this study did
NCT04205838 · Jonsson Comprehensive Cancer Center
2020-03-04 – 2026-02-19 · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT06710197 · University Health Network, Toronto
2025-03-05 – 2026-02-12 · Early Stage Triple Negative ER Low Breast Cancer
What this study did
NCT04834388 · Radboud University Medical Center
2022-08-10 – 2025-12 · Intracerebral Hemorrhage
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT05914454 · Azienda Sanitaria-Universitaria Integrata di Udine
2023-05-19 – 2025-09-19 · Acute Respiratory Distress Syndrome
What this study did
NCT03925194 · Heidelberg University
2022-12-01 – 2025-07-25 · Cystic Fibrosis, 10011762
What this study did
NCT04359784 · Fred Hutchinson Cancer Center
2021-12-27 – 2024-12-23 · B-Cell Non-Hodgkin Lymphoma
What this study did
NCT04150913 · Marcela V. Maus, M.D.,Ph.D.
2020-10-01 – 2024-10-31 · Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
What this study did
NCT03797001 · Virginia Commonwealth University
2019-01-04 – 2024-07-22 · Heart Failure, Systolic, Inflammation
What this study did
NCT04017936 · Virginia Commonwealth University
2020-10-23 – 2024-06-30 · Cardiac Sarcoidosis
What this study did
NCT05785442 · Hellenic Institute for the Study of Sepsis
2023-03-06 – 2024-06-28 · Community-acquired Pneumonia, Hospital-acquired Pneumonia
What this study did
NCT04227769 · University Hospital, Basel, Switzerland
2020-01-13 – 2024-05-28 · Diabetes Mellitus Type 2 in Obese, Inflammation, Metabolic Disease, Glucose Metabolism Disorders (Including Diabetes Mellitus)
What this study did
NCT04432506 · M.D. Anderson Cancer Center
2020-07-27 – 2024-05-28 · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05854251 · University Hospital, Basel, Switzerland
2023-06-15 – 2024-05-17 · Hyperinsulinemia, PreDiabetes
What this study did
NCT04990232 · Hellenic Institute for the Study of Sepsis
2021-07-29 – 2024-04-27 · Sepsis
What this study did
NCT04099901 · Radboud University Medical Center
2019-11-04 – 2024-02-26 · Multiple Myeloma
What this study did
NCT04603742 · Weill Medical College of Cornell University
2021-12 – 2022-09 · Covid19, Cytokine Storm, Mechanical Ventilation Complication
What this study did
NCT04072822 · Indiana University
2020-07-10 – 2022-08-12 · Alcoholic Hepatitis
What this study did
NCT04357366 · Hellenic Institute for the Study of Sepsis
2020-04-15 – 2022-04-15 · COVID-19, Virus Diseases, Corona Virus Infection, Lower Respiratory Tract Infection Viral
What this study did
NCT02929251 · Assistance Publique - Hôpitaux de Paris
2017-06-29 – 2022-01-29 · Uveitis, Biotherapy
What this study did
NCT02997371 · Adel Helmy
2017-10 – 2021-10 · Traumatic Brain INjury
What this study did
NCT03141983 · University of Pennsylvania
2017-12-15 – 2021-09-02 · End-Stage Renal Disease
What this study did
NCT03737344 · Adrian Parry-Jones
2019-05-17 – 2021-04-30 · Intracerebral Haemorrhage
What this study did
NCT04339712 · Hellenic Institute for the Study of Sepsis
2020-04-02 – 2021-01-08 · COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
What this study did
NCT04462757 · University of Manchester
2020-05-28 – 2020-12-23 · COVID-19
What this study did
NCT02930122 · Cale Jacobs, PhD
2019-06-20 – 2020-10-16 · Anterior Cruciate Ligament Tear
What this study did
NCT04366232 · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
2020-08-19 – 2020-10-02 · Covid-19
What this study did
NCT03578497 · University Hospital, Basel, Switzerland
2018-08-31 – 2020-07-30 · Polycystic Ovary Syndrome
What this study did
NCT04341584 · Assistance Publique - Hôpitaux de Paris
2020-04-08 – 2020-07-25 · Corona Virus Infection
What this study did
NCT03233776 · Radboud University Medical Center
2017-08-21 – 2020-04-02 · Multiple Myeloma
What this study did
NCT03224585 · Virginia Commonwealth University
2018-05-11 – 2020-02-01 · Acute Pericarditis
What this study did
NCT03332225 · Hellenic Institute for the Study of Sepsis
2017-12-15 – 2019-12-31 · Sepsis, Macrophage Activation Syndrome
What this study did
NCT01794117 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2013-07-22 – 2019-10-07 · Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
What this study did
NCT03002974 · Swedish Orphan Biovitrum
2016-12 – 2019-08 · Acute Gouty Arthritis
What this study did
Phase 1/2 (22)
Other / comorbidity
Dupilumab_Metastatic NSCLCactive not recruiting
NCT05013450 · Thomas Marron
2021-09-10 – 2030-09-18 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06703216 · Kevin McNerney
2026-10 – 2030-02-28 · B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
What this study did
NCT07503834 · Nantes University Hospital
2026-10-07 – 2029-04-07 · Pancreatic Transplant
What this study did
NCT07888348 · Ruijin Hospital
2026-10-05 – 2028-11-15 · Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
What this study did
NCT05280340 · Monash Medical Centre
2022-02-15 – 2025-03 · Prematurity; Extreme, Inflammation
What this study did
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT04025554 · National Institute of Neurological Disorders and Stroke (NINDS)
2019-10-25 – 2023-10-24 · Multiple Sclerosis
What this study did
NCT04035109 · University of North Carolina, Chapel Hill
2019-12-16 – 2023-10 · Asthma, Allergic
What this study did
NCT03430011 · Juno Therapeutics, a Subsidiary of Celgene
2018-02-01 – 2023-03-30 · Multiple Myeloma
What this study did
NCT04018755 · Lynda E Polgreen
2020-01-30 – 2023-03-08 · Mucopolysaccharidosis III
What this study did
NCT02179853 · University of California, San Diego
2014-11 – 2022-12 · Kawasaki Disease
What this study did
NCT03513471 · University of North Carolina, Chapel Hill
2019-08-09 – 2021-12 · Asthma
What this study did
NCT03513458 · University of North Carolina, Chapel Hill
2020-09 – 2021-12 · Asthma
What this study did
NCT02547766 · University of Utah
2015-04 – 2016-12 · Heart Failure
What this study did
NCT02414152 · Andrea Vambutas
2013-10 – 2015-07 · Hearing Loss, Sudden
What this study did
NCT01441076 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2011-09 – 2014-11 · Autoimmune Connective Tissue Disorder, Immune System Diseases
What this study did
NCT01267994 · Andrea Vambutas
2011-06 – 2014-09 · Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
What this study did
NCT01479010 · Virginia Commonwealth University
2011-11 – 2013-11 · Pulmonary Hypertension
What this study did
NCT01300650 · Virginia Commonwealth University
2011-02 – 2011-08 · Heart Failure
What this study did
NCT00069329 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2003-09 – 2010-04 · Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
What this study did
NCT00645840 · University of Texas Southwestern Medical Center
2008-03 – 2009-09 · Type 1 Diabetes Mellitus
What this study did
NCT00332254 · Duke University
2006-03 – 2007-06 · Knee Injury
What this study did
Phase 1 (26)
Other / comorbidity
NCT06974877 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-09-10 – 2032-01-31 · Cryopyrin-Associated Periodic Syndromes, Amyloidosis
What this study did
NCT07838974 · University of Southern California
2026-11-01 – 2030-11-01 · Melanoma
What this study did
NCT07600190 · University of North Carolina, Chapel Hill
2026-11-01 – 2029-01-01 · Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
What this study did
NCT07410312 · Northwestern University
2026-10-01 – 2027-12 · Lung Transplant Recipient
What this study did
NCT03968913 · University of California, Los Angeles
2021-09-15 – 2027-01-30 · Anterior Cruciate Ligament Injuries
What this study did
NCT06062966 · Virginia Commonwealth University
2024-02-05 – 2026-06-01 · Heart Failure
What this study did
NCT05074485 · Alan Prossin
2021-07-19 – 2026-05-07 · Pain
What this study did
NCT04942626 · Goethe University
2021-08-20 – 2024-12-31 · Rectal Cancer
What this study did
NCT02780583 · University of Alabama at Birmingham
2016-05-15 – 2024-04-30 · Macrophage Activation Syndrome
What this study did
NCT04691765 · Dr. David Spaner
2021-05-01 – 2022-12 · Chronic Lymphocytic Leukemia
What this study did
NCT04227275 · Tceleron Therapeutics, Inc.
2019-11-22 – 2022-11-07 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT04747847 · University of California, San Diego
2019-06-22 – 2022-08-17 · Kawasaki Disease
What this study did
NCT03991520 · University of California, San Diego
2020-06-16 – 2022-01 · Endometriosis, Anakinra, Markers of Inflammation
What this study did
NCT02550327 · Baylor Research Institute
2016-01 – 2021-06-14 · Pancreatic Adenocarcinoma
What this study did
NCT02021422 · Baylor Research Institute
2013-12 – 2021-06 · Pancreas Cancer
What this study did
NCT01624766 · M.D. Anderson Cancer Center
2012-06-19 – 2021-02-24 · Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
What this study did
NCT04136028 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2015-09-25 – 2020-01 · Chronic Granulomatous Disease
What this study did
NCT02492750 · Mayo Clinic
2016-04 – 2019-09-13 · Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
What this study did
NCT03057028 · Virginia Commonwealth University
2016-04 – 2018-06-07 · Pulmonary Arterial Hypertension
What this study did
NCT02527460 · National Institute of Neurological Disorders and Stroke (NINDS)
2015-08-17 – 2018-03-02 · HIV Infections, Neurologic Disorders
What this study did
NCT01802970 · Baylor Research Institute
2012-12 – 2017-01-04 · Metastatic Breast Cancer
What this study did
NCT00072111 · National Cancer Institute (NCI)
started 2003-09 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01122914 · National Institute of Allergy and Infectious Diseases (NIAID)
2010-04-14 – 2015-04-07 · Anakinra, Kineret, Atopic Dermatitis, Eczema, Allergic Disease
What this study did
NCT01810549 · University of Zurich
2013-03 – 2013-12 · Postprandial Fatigue
What this study did
NCT01369017 · Michelle Hernandez, MD
2011-10 – 2013-07 · Healthy Control Subjects
What this study did
NCT00214851 · Nova Scotia Health Authority
2005-09 – 2005-12 · Familial Cold Urticaria
What this study did
Phase 4 (9)
Rheumatoid Arthritis
NCT02236481 · Prof. Roberto Giacomelli
2013-07 – 2017-12 · Diabetes Mellitus, Type 2, Arthritis, Rheumatoid
What this study did
NCT00121043 · Amgen
— · Rheumatoid Arthritis
What this study did
NCT00111410 · Amgen
est. completion 2003-11 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07706868 · Swedish Orphan Biovitrum
2025-09-01 – 2028-09-30 · Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD)
What this study did
NCT06666335 · Swedish Orphan Biovitrum
2026-03-01 – 2027-11-30 · Familial Mediterranean Fever (FMF )
What this study did
NCT06697431 · Meyer Children's Hospital IRCCS
2026-04-01 – 2027-04-01 · Kawasaki Disease, Anakinra
What this study did
NCT06624436 · Radboud University Medical Center
2024-10-24 – 2025-12 · Sepsis, Neuroinflammatory Response, Immunosuppresion, Endotoxemia, Anakinra, Dexamethasone, Tocilizumab
What this study did
NCT01997138 · Oslo University Hospital
2016-03 – 2018-09 · Knee Injuries
What this study did
NCT02219828 · Massimo Imazio
2014-06 – 2015-10 · Idiopathic Recurrent Pericarditis
What this study did
Early phase / not applicable (10)
Rheumatoid Arthritis
NCT01566201 · University of Athens
2011-03 – 2013-06 · Rheumatoid Arthritis, Coronary Artery Disease, Inflammation
What this study did
Other / comorbidity
NCT06071156 · Azienda Ospedaliero, Universitaria Ospedali Riuniti
2018-01-01 – 2025-01-31 · Recurrent Pericarditis
What this study did
NCT05279391 · Democritus University of Thrace
2020-10-25 – 2023-12-31 · COVID-19 Severe Respiratory Failure
What this study did
NCT03200782 · University Hospital, Basel, Switzerland
2017-05-30 – 2018-09-21 · Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping Syndrome
What this study did
NCT02916355 · University Hospital, Basel, Switzerland
2016-08 – 2017-04-03 · Adiposity
What this study did
NCT02310009 · Copenhagen University Hospital, Rigshospitalet
2014-12 – 2015-07-30 · Type 2 Diabetes Mellitus
What this study did
NCT01542502 · Virginia Commonwealth University
2012-02 – 2013-06 · Heart Failure
What this study did
NCT01466764 · Stanford University
2011-10 – 2013-06 · Pain, Inflammation
What this study did
NCT01285232 · Radboud University Medical Center
2011-01 – 2012-12 · Glucose Intolerance, Impaired Insulin Secretion, Diabetes Mellitus Type 2
What this study did
NCT00420290 · Vanderbilt University
2008-01 – 2010-05 · End Stage Renal Disease
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (2)
Other / comorbidity
NCT04544813 · Janssen Research & Development, LLC
2020-10-13 – 2021-05-30 · Healthy
What this study did
NCT02175056 · Handok Inc.
2014-05 – 2015-02 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Anakinra: this drugApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 23 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Anakinra to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3FMFRecruiting
Est. primary completion 2026-12-04 · NCT06336733 · CT.gov ↗
What to watch
2027 (9)
January 2027 (1)
Phase 1Anterior Cruciate Ligament InjuriesRecruiting
Est. primary completion 2027-01-30 · NCT03968913 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Heart FailureActive not recruiting
Est. primary completion 2027-02-22 · NCT05177822 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Kawasaki DiseaseRecruiting
Est. primary completion 2027-03 · NCT04656184 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT04926467 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Lung Transplant RecipientNot yet recruiting
Est. primary completion 2027-08 · NCT07410312 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10 · NCT04148430 · CT.gov ↗
What to watch
Phase 3PericarditisRecruiting
Est. primary completion 2027-10-01 · NCT05805930 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell TransplantationNot yet recruiting
Est. primary completion 2027-11-15 · NCT07888348 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Autoimmune Inner Ear Disease, Meniere's DiseaseRecruiting
Est. primary completion 2027-12-31 · NCT03587701 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2/3Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVIDRecruiting
Est. primary completion 2028-03 · NCT05926505 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2/3Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)Recruiting
Est. primary completion 2028-05-15 · NCT05267821 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP) …Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2SepsisRecruiting
Est. primary completion 2028-08-09 · NCT06381661 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3PneumoniaRecruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 1Asthma (Diagnosis), Persistent Asthma, Moderate Asthma ExacerbationNot yet recruiting
Est. primary completion 2029-01-01 · NCT07600190 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Pancreatic TransplantRecruiting
Est. primary completion 2029-04-07 · NCT07503834 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1MelanomaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07838974 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3PEDIATRIC ACUTE MYOCARDITISNot yet recruiting
Est. primary completion 2029-12 · NCT07371689 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 3New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)Not yet recruiting
Est. primary completion 2030-03-31 · NCT07281027 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 1Cryopyrin-Associated Periodic Syndromes, AmyloidosisRecruiting
Est. primary completion 2031-07-01 · NCT06974877 · CT.gov ↗
What to watch

See the full readout calendar ↗